Smoking and COVID-19: new study investigates immune cell changes
NCT ID NCT04403386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 132 healthy smokers and non-smokers aged 30-55 to see how smoking history affects immune cells and COVID-19 risk. Participants provided blood, saliva, and nasal swab samples over up to six monthly visits. The goal is to understand why smokers may have more severe COVID-19 outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help explain why smokers face higher risks from COVID-19 and guide future prevention strategies.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NIEHS Clinical Research Unit (CRU)
Research Triangle Park, North Carolina, 27709, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?